Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
» AUXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AUXL Guru Trades in Q2 2014

Louis Moore Bacon 150,000 sh (New)
John Paulson 4,000,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2014

AUXL Guru Trades in Q3 2014

Mario Gabelli 10,900 sh (New)
John Paulson 4,000,000 sh (unchged)
Louis Moore Bacon 100,000 sh (-33.33%)
» More
Q4 2014

AUXL Guru Trades in Q4 2014

Jim Simons 468,040 sh (New)
Jeremy Grantham 1,281,312 sh (New)
Mario Gabelli 35,885 sh (+229.22%)
Louis Moore Bacon Sold Out
John Paulson Sold Out
» More
Q1 2015

AUXL Guru Trades in Q1 2015

Jim Simons Sold Out
Jeremy Grantham Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AUXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue(Mil) $407
EPS $ -2.99
Short Percentage of Float29.16%
52-Week Range $17.10 - 37.93
Shares Outstanding(Mil)51.02

Analyst Estimate

Dec14 Dec15 Dec16
Revenue(Mil) 388 448 518
EPS($) -0.05 2.60 3.50
EPS without NRI($) -0.05 2.60 3.50

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FEJ.Germany,
Auxilium Pharmaceuticals, Inc., incorporated in the state of Delaware in July 1999. The Company is a specialty biopharmaceutical company which develops and markets products for specialist audiences. The Company now have a portfolio of 12 approved products, including one product with two indications. Among other products in the U.S., Auxilium markets Testim (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL (testosterone pellets) a long-acting implantable testosterone replacement therapy ("TRT") product, STENDRA (avanafil), an oral erectile dysfunction ("ED") therapy, Edex (alprostadil for injection), an injectable treatment for ED, Osbon ErecAid, the leading vacuum device for aiding ED, XIAFLEX (collagenase clostridium histolyticum or "CCH") for the treatment of Peyronie's disease ("PD" or "Peyronie's") and XIAFLEX for the treatment of Dupuytren's contracture ("DC" or "Dupuytren's"). We also have programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite, Striant, a buccal TRT, XIAFLEX for the treatment of PD in men with a palpable plaque and a curvature deformity of thirty degrees or greater at the start of therapy which was launched in the U.S. in January 2014 and is the first and only FDA-approved non-surgical treatment for PD. Approximately 75% of the Company's product shipments are to only three wholesalers: Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation. The Company faces competition from competitors in North America, Europe and elsewhere from pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products.
» More Articles for AUXL

Headlines

Articles On GuruFocus.com
Endo International Posts Upbeat Q1 Results May 13 2015 
Endo Pharmaceuticals Posts A Solid Q1 Earnings Report May 12 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 16 2009 

More From Other Websites
Pozen to redomicile as it agrees to buy Tribute Pharmaceuticals Jun 08 2015
Endo International (ENDP) Earnings Report: Q1 2015 Conference Call Transcript May 11 2015
Endo (ENDP) Beats on Q1 Earnings, 2015 Guidance Updated - Tale of the Tape May 11 2015
13F Watch: In Defense of Active Share Feb 19 2015
Auxilium Announces Fundamental Change and Make-Whole Fundamental Change Relating to Outstanding... Feb 03 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Jan 30 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 29 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jan 27 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 21 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 16 2015
Auxilium reports 3Q loss Oct 30 2014
Auxilium reports 3Q loss Oct 30 2014
Endo bolsters men's healthcare business with Auxilium deal Oct 09 2014
Auxilium Pharma accepts Endo's buyout offer, drops QLT deal Oct 09 2014
Endo Intl to buy Auxilium in deal worth $2.6B Oct 09 2014
Endo Intl to buy Auxilium in deal worth $2.6B Oct 09 2014
US STOCKS-Futures turn lower as global growth concerns weigh Oct 09 2014
Endo to buy Auxilium for $2.6 bln, Auxilium drops QLT deal Oct 09 2014
Moody's says may review M&As if new tax rules lead to altered terms Sep 23 2014
Auxilium says Endo offer undervalues company, but open to talks Sep 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK